288 related articles for article (PubMed ID: 22494267)
21. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
22. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
23. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Migliaccio-Walle K; Rublee D; Simon TA
Postgrad Med; 2012 Jan; 124(1):41-9. PubMed ID: 22314113
[TBL] [Abstract][Full Text] [Related]
25. New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Hamidi V; Ringerike T; Hagen G; Reikvam Å; Klemp M
Int J Technol Assess Health Care; 2013 Jul; 29(3):234-43. PubMed ID: 23768996
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
28. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
29. Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
Verhamme P; Gunn S; Sonesson E; Peerlinck K; Vanassche T; Vandenbriele C; Ageno W; Glazer S; Prins M; Buller H; Tangelder M
Thromb Haemost; 2013 Jun; 109(6):1091-8. PubMed ID: 23615791
[TBL] [Abstract][Full Text] [Related]
30. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST; Scott LJ; Plosker GL
Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
[TBL] [Abstract][Full Text] [Related]
32. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review.
Brockbank J; Wolowacz S
Pharmacoeconomics; 2017 May; 35(5):517-535. PubMed ID: 28185212
[TBL] [Abstract][Full Text] [Related]
33. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
[TBL] [Abstract][Full Text] [Related]
34. Drug interactions with rivaroxaban following total joint replacement surgery.
Kwong LM; Tong LM
Ann Pharmacother; 2012 Sep; 46(9):1232-8. PubMed ID: 22932305
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
36. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
Rashki Kemmak A; Abutorabi A; Alipour V
Clin Drug Investig; 2020 Aug; 40(8):715-725. PubMed ID: 32578155
[TBL] [Abstract][Full Text] [Related]
37. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
